|
|
|
|
LEADER |
01262nam a2200241 u 4500 |
001 |
EB002010812 |
003 |
EBX01000000000000001173711 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
220201 r ||| eng |
100 |
1 |
|
|a Edge, Rob
|
245 |
0 |
0 |
|a PET diagnostic imaging with prostate-specific membrane antigen for prostate cancer
|h Elektronische Ressource
|b a review of clinical utility, cost-effectiveness, diagnostic accuracy, and guidelines
|c Rob Edge, Lory Picheca
|
250 |
|
|
|a Version:1.0
|
260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c November 17, 2020, 2020
|
300 |
|
|
|a 1 PDF file (37 pages)
|b illustration
|
700 |
1 |
|
|a Picheca, Lory
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567203
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a This report aims to retrieve and review the cost-effectiveness, diagnostic accuracy, and evidence-based guidelines regarding PSMA PET imaging for patients with suspected or confirmed metastatic or BCR of prostate cancer
|